Novartis notifies about Phase III COMBI-I study to treat skin cancer

By Nikita Chaurasia  Date: 2020-08-24

Novartis notifies about Phase III COMBI-I study to treat skin cancer

Reportedly, Novartis made an announcement that the COMBI-I study in its third phase that does evaluation of investigational immunotherapy spartalizumab (PDR001), combined with the targeted therapies Mekinist (trametinib) and Tafinlar (dabrafenib) did not produce a primary result of progression-free, investigator-assessed survival.

As per the trusted sources, the trail was conducted on untreated patients with metastatic (Stage IV) BRAF V600 or unresectable (Stage IIIC) mutation-positive cutaneous melanoma, in comparison with Tafinlar + Mekinist treatment alone. Tafinlar and Mekinist are medicines prescribed in combination to treat patients with skin cancer- melanoma.

John Tsai, MD, Chief Medical Officer and Head of Global Drug Development at Novartis states that although the COMBI-I trial did not get to its primary outcome, the report’s analysis offers some important insights of its part like the investigational immunotherapy spartalizumab could possibly contribute to the future cancer therapy combinations. Besides this, it also highlights the significance of Tafinlar + Mekinist for these patients as estimated in the past.

He further added that Novartis is fully dedicated towards curing melanoma patients through ongoing study and they would continue to provide the approved combination therapy Tafinlar + Mekinist to patients across the globe.

He added that they at Novartis extend gratitude to the patients and investigators who took part in the COMBI-I study and claimed that their collaboration has raised understanding of spartalizumab and its potential role in future cancer treatments at Novartis.

Reportedly, COMBI-I study investigators and people at Novartis will continue to analyze the data to gain more information from the results, which are likely to be taken forward to a presentation at a future medical meeting.

Novartis continues to search for more uses of immunotherapy in cancer treatment, along with the latest ongoing development of spartalizumab, across a plethora of tumors.  

Source credits-

https://www.novartis.com/news/media-releases/novartis-provides-update-phase-iii-study-evaluating-investigational-spartalizumab-pdr001-combination-tafinlar-mekinist-advanced-melanoma

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

TCS, Infosys, Accenture workforce to receive free Covid-19 vaccination

TCS, Infosys, Accenture workforce to receive free Covid-19 vaccination

By Nikita Chaurasia

Information technology giants Infosys, Accenture India, and Tata Consultancy Services will reportedly cover Covid-19 vaccination costs for their employees and their family, who are eligible and opt to receive the jab. This news comes along the heels...

Motorola Solutions to offer Norwegian Health Emergency Service with CRS

Motorola Solutions to offer Norwegian Health Emergency Service with CRS

By Nikita Chaurasia

Motorola Solutions has announced to have been selected by Helsetjenestens Driftsorganisasjon for Nødnett HF (HDO HF) to offer the Norwegian Health Emergency Service with a new CRS (Command Central Control Room Solution). Confirming the news,&...

Nestle India exploring options to directly sell products to consumers

Nestle India exploring options to directly sell products to consumers

By Nikita Chaurasia

Nestle India Ltd. is reportedly exploring their options of trying their hands at direct selling since consumers are largely turning towards the internet to purchase products ranging from staples to medicines amidst the COVID-19 pandemic. While the n...

Razorpay: New funding en route, meteoric rise in market value expected

Razorpay: New funding en route, meteoric rise in market value expected

By Nikita Chaurasia

Indian startup Razorpay is reportedly in discussions with Singapore-based sovereign wealth fund GIC Pvt. Ltd. and other existing investors to raise around USD 200 million in a funding round that would allow the fintech company to double its valuation...

FDA to allow pharma companies modify COVID-19 shots amid variants surge

FDA to allow pharma companies modify COVID-19 shots amid variants surge

By Nikita Chaurasia

With the rising cases of Coronavirus variants, the United States Food & Drug Administration (FDA) has reportedly introduced guidelines for pharmaceutical companies to modify their COVID-19 vaccine doses in an effort to curb the spread of the dise...